Fred Aslan

CEO

Insider activity · 24 months0 buys9 salesCumulative net flow

Dec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 1 saleSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 1 saleNov 25 · 0 buys · 1 saleDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 2 salesOct 26 · 0 buys · 2 salesNov 26 · 0 buys · 1 sale

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (9 ops.)

€1.8M

Latest filing published 03 Nov 2026 for Artiva Biotherapeutics, Inc., €233k.

Filing timeline

BuySale

Fred Aslan

Insider track record

Disclosed buys

Disclosed sells

Signal history

Fred Aslan: trading record in brief

All filings by Fred Aslan on record concern Artiva Biotherapeutics, Inc. The record holds 19 filings, for trades running from 22 July 2024 to 2 November 2026.

Every open-market trade on record is a sale: 9 sales worth €1.8M. Outside the open market, there are 10 share grants. 2026 to date brings no purchases and 5 sales.

The newest entry dates from 3 November 2026: an open-market sale of €233k, in Artiva Biotherapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Fred Aslan

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Artiva Biotherapeutics, Inc. (US)

Declarations19 total

▼
Fred Aslan
Chief Executive OfficerExecutives2 Nov 2026Artiva Biotherapeutics, Inc.
259,972 USD0SEC
62,178 shares@ US$4.1811Common StockSEC:0001193125-26-445312:0
▼
Fred Aslan
Chief Executive OfficerExecutives6 Oct 2026Artiva Biotherapeutics, Inc.
168,880 USD52SEC
23,463 shares@ US$7.19770.051% mcap9.9% of flowCommon StockSEC:0001193125-26-416953:0
▼
Fred Aslan
Chief Executive OfficerExecutives5 Oct 2026Artiva Biotherapeutics, Inc.
421,828 USD56SEC
61,696 shares@ US$6.83720.13% mcap27.5% of flowCommon StockSEC:0001193125-26-415527:0
◆
Fred Aslan
Chief Executive OfficerExecutives15 Sept 2026Artiva Biotherapeutics, Inc.
0SEC
110,000 shares0Common StockSEC:0001193125-26-392025:0
◆
Fred Aslan
Chief Executive OfficerExecutives10 Sept 2026Artiva Biotherapeutics, Inc.
0SEC
45,000 shares0Common StockSEC:0001193125-26-391012:0
▼
Fred Aslan
Chief Executive OfficerExecutives8 Sept 2026Artiva Biotherapeutics, Inc.
255,746 USD53SEC
23,429 shares@ US$10.91580.086% mcap13.3% of flowCommon StockSEC:0001193125-26-386431:0
▼
Fred Aslan
Chief Executive OfficerExecutives3 Sept 2026Artiva Biotherapeutics, Inc.
690,392 USD58SEC
61,888 shares@ US$11.15550.22% mcap36.0% of flowCommon StockSEC:0001193125-26-383618:0
◆
Fred Aslan
President and CEOExecutives15 Feb 2026Artiva Biotherapeutics, Inc.
58,400 USD22SEC
14,600 shares@ US$4.003.0% of flowCommon StockSEC:0001193125-26-057667:1
◆
Fred Aslan
President and CEOExecutives15 Feb 2026Artiva Biotherapeutics, Inc.
0SEC
366,850 shares0Common StockSEC:0001193125-26-057667:0
▼
Fred Aslan
President and CEOExecutives15 Dec 2025Artiva Biotherapeutics, Inc.
19,122 USD22SEC
3,187 shares@ US$6.001.6% of flowCommon StockSEC:0001193125-25-319696:0
◆
Fred Aslan
President and CEOExecutives12 Dec 2025Artiva Biotherapeutics, Inc.
0SEC
869,136 shares0Common StockSEC:0001193125-25-317980:0
▼
Fred Aslan
President and CEOExecutives17 Nov 2025Artiva Biotherapeutics, Inc.
21,548 USD22SEC
6,375 shares@ US$3.381.1% of flowCommon StockSEC:0001193125-25-285004:1
◆
Fred Aslan
President and CEOExecutives15 Nov 2025Artiva Biotherapeutics, Inc.
20,628 USD22SEC
6,347 shares@ US$3.251.8% of flowCommon StockSEC:0001193125-25-285004:0
▼
Fred Aslan
President and CEOExecutives17 Oct 2025Artiva Biotherapeutics, Inc.
153,000 USD23SEC
25,500 shares@ US$6.0013.2% of flowCommon StockSEC:0001909362-25-000004:0
▼
Fred Aslan
President and CEOExecutives15 Aug 2025Artiva Biotherapeutics, Inc.
69,615 USD22SEC
25,500 shares@ US$2.733.6% of flowCommon StockSEC:0001415889-25-022224:1
◆
Fred Aslan
President and CEOExecutives15 Aug 2025Artiva Biotherapeutics, Inc.
12,298 USD22SEC
4,472 shares@ US$2.750.6% of flowCommon StockSEC:0001415889-25-022224:2
◆
Fred Aslan
President and CEOExecutives15 May 2025Artiva Biotherapeutics, Inc.
9,525 USD22SEC
4,472 shares@ US$2.130.9% of flowCommon StockSEC:0001415889-25-022224:0
◆
Fred Aslan
President and CEOExecutives5 Mar 2025Artiva Biotherapeutics, Inc.
0SEC
200,000 shares0Common StockSEC:0001415889-25-007431:0
◆
Fred Aslan
President and CEOExecutives22 Jul 2024Artiva Biotherapeutics, Inc.
0SEC
228,905 shares0Common StockSEC:0001415889-24-019905:0

19 of 19 declarations

Fred Aslan

Insider track record

Fred Aslan: trading record in brief

Companies and markets linked to Fred Aslan

Related entities